Home
Conditions
Multiple Myeloma

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,606 public trials 492 recruiting studies

Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Active, Not Recruiting

Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma

NCT06073353

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Massachusetts General Hospital Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

NCT05002816

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Yale New Haven Hospital New Haven, Connecticut, United States

View Trial Details

Active, Not Recruiting

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

NCT05981209

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, Not Recruiting

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

NCT05514990

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Los Angeles County-USC Medical Center Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Active, Not Recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

NCT03844048

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +31 more
Locations: University of Arizona Cancer Center - Tucson /ID# 210548 Tucson, Arizona, United States

UCLA Santa Monica Hematology Oncology /ID# 210551 Los Angeles, California, United States

Ingalls Memorial Hosp /ID# 210553 Harvey, Illinois, United States

Dana-Farber Cancer Institute /ID# 215360 Boston, Massachusetts, United States

View all 56 locations

View Trial Details

Active, Not Recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

NCT06400225

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT05497804

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic Jacksonville, Florida, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Active, Not Recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

NCT06385496

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401

Conditions: Acute Myeloid Leukemia, Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, +98 more
Locations: Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis Daphne, Alabama, United States

Thomas Hospital Fairhope, Alabama, United States

Mobile Infirmary Medical Center Mobile, Alabama, United States

Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland Saraland, Alabama, United States

View all 150 locations

View Trial Details

Active, Not Recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

NCT06390865

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Multiple Myeloma

Multiple Myeloma trial results

Related conditions